ISBN-10:
0128203277
ISBN-13:
9780128203279
Pub. Date:
08/10/2020
Publisher:
Elsevier Science
Advances in Cancer Research

Advances in Cancer Research

by Elsevier ScienceElsevier Science
Current price is , Original price is $171.0. You

Temporarily Out of Stock Online

Please check back later for updated availability.

Overview

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics.


  • Provides invaluable information on the exciting and fast-moving field of cancer research
  • Presents outstanding and original reviews on a variety of topics

Product Details

ISBN-13: 9780128203279
Publisher: Elsevier Science
Publication date: 08/10/2020
Series: Advances in Cancer Research Series , #148
Pages: 330
Product dimensions: 6.00(w) x 9.00(h) x 0.75(d)

About the Author

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Table of Contents

1. Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity Liliya Tyutyunyk-Massey, Syed Haqqani, Reshma Mandava, Kirubel Kentiba, Mallika Dammalapati, Nga Dao, Joshua Haueis, David Gewirtz and Joseph W. Landry 2. VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation Diana Fang and Eduardo N. Maldonado 3. Acquired Resistance to Drugs Targeting Tyrosine Kinases Steven A. Rosenzweig 4. Extracellular Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes Scott T. Eblen 5. Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases Mitchell E. Menezes, Praveen Bhoopathi, Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Chunqing Guo, Xiang-Yang Wang, Devanand Sarkar and Paul B. Fisher 6. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics Jesse J. McClure, Xiaoyang Li and C. James Chou 7. Prospects of Gene Therapy to Treat Melanoma Mitchell E. Menezes, Sarmistha Talukdar, Stephen L. Wechman, Swadesh K. Das, Luni Emdad, Devanand Sarkar and Paul B. Fisher

Customer Reviews